Budesonide treatment for microscopic colitis from immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as enterocolitis. Enterocolitis is typically treated with systemically active glucocorticoids. Endoscopy can stratify patients by the severity of mucosal inflammation, including identifying patients with colitis in the absence of visible mucosal changes: microscopic colitis. Whether patients with CPI microscopic colitis could be managed differently from colitis with more severe mucosal involvement is unclear. The objective of this study was to describe outcomes in CPI microscopic colitis focusing on the response to first line treatment with budesonide.

Methods

We evaluated data from a retrospective cohort from a single-center large

SUBMITTER: Hughes MS 

PROVIDER: S-EPMC6839080 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature